Innovating Works

MHH

Desconocido
Mostrando 1 al 20 de 166 resultados
RESOLVE: Residual disease assessment in hematologic malignancies to improve patient-relevant outcomes across... MEDIZINISCHE HOCHSCHULE HANNOVER tramitó un HORIZON EUROPE: HORIZON-MISS-2023-CANCER-01 "MeMeasurable residual disease (MRD) detected by multiparameter flow cytometry (MFC) has strong prognostic value in patients with the most f...
2024-04-01 - 2029-03-31 | Financiado
iMAClung: Moving cell-based immunotherapies to fight bacterial lung infections into the clinics MEDIZINISCHE HOCHSCHULE HANNOVER tramitó un HORIZON EUROPE: ERC-2023-POC Harnessing the immune system to combat global diseases has introduced a new era in modern medicine. The iMAClung proposal will extend this c...
2024-02-08 - 2025-09-30 | Financiado
KSHV-RBPome: Elucidating the role of RNA-binding proteins in Kaposi’s sarcoma-associated herpesvirus infected cel... MEDIZINISCHE HOCHSCHULE HANNOVER tramitó un HORIZON EUROPE: HORIZON-MSCA-2022-PF-01 Kaposi’s sarcoma-associated herpesvirus (KSHV), an oncogenic human γ-herpesvirus, is the cause of Kaposi’s Sarcoma (KS), primary effusion ly...
2023-08-02 - 2026-07-31 | Financiado
PIECES: TOWARDS LARGE SCALE ADAPTION AND TAILORED IMPLEMENTATION OF EVIDENCE BASED PRIMARY CANCER PREVENTION... MEDIZINISCHE HOCHSCHULE HANNOVER participó en un HORIZON EUROPE: HORIZON-MISS-2022-CANCER-01 The high and growing global burden of cancer urges the need for effective implementation of primary cancer prevention (PCP) programmes targe...
2023-04-24 - 2027-05-31 | Financiado
HyperTargIPS-NK: Hyper-targeting CAR NK cells from induced pluripotent stem cells for novel off-the-shelf anti-tumor... MEDIZINISCHE HOCHSCHULE HANNOVER participó en un HORIZON EUROPE: HORIZON-EIC-2022-PATHFINDEROPEN-01 The HyperTargIPS-NK project aims to combine novel technologies from three research laboratories and a stem cell company to develop a revolut...
2023-01-19 - 2026-03-31 | Financiado
iPYRO: Custom-Made Designer Macrophages to Revolutionize the Safety of Parenteral Drugs MEDIZINISCHE HOCHSCHULE HANNOVER tramitó un HORIZON EUROPE: ERC-2022-POC2 The iPYRO proposal is built upon the uniqueness of human induced pluripotent stem cells (iPSC) and recent innovations in the farming of full...
2022-11-23 - 2024-06-30 | Financiado
READIHEAR: Rehabilitation and Diagnosis of Hearing Loss based on Electric Acoustic Interaction MEDIZINISCHE HOCHSCHULE HANNOVER tramitó un HORIZON EUROPE: ERC-2021-COG Hearing loss is the most common sensory deficit in the elderly, and it is becoming a severe social as well as a health problem. Across the w...
2022-09-21 - 2027-11-30 | Financiado
MY-O-SENSES: Pre-clinical development of a lentiviral gene therapy to treat hearing and balance loss in Usher 1B... MEDIZINISCHE HOCHSCHULE HANNOVER tramitó un HORIZON EUROPE: ERC-2022-POC2 The most prevalent genetic sensory defect, sensorineural hearing loss (SNHL), affects >430 million people and results in substantial financi...
2022-08-08 - 2024-02-29 | Financiado
AAVolution: Next-generation AAV vectors for liver-directed gene therapy MEDIZINISCHE HOCHSCHULE HANNOVER participó en un HORIZON EUROPE: HORIZON-EIC-2021-PATHFINDERCHALLENGES-01 Liver-directed gene therapy has undergone significant development in the last two decades. Recombinant adeno-associated vectors (AAV) are th...
2022-07-11 - 2026-09-30 | Financiado
REVERSE: Circular RNAs to reverse pathological remodelling of the injured heart MEDIZINISCHE HOCHSCHULE HANNOVER tramitó un HORIZON EUROPE: ERC-2021-ADG Heart failure (HF) is a most common cause of mortality with currently >60 million of affected patients. Numbers will increase due to socioec...
2022-05-31 - 2027-09-30 | Financiado
D-SOLVE: Understanding the individual host response against Hepatitis D Virus to develop a personalized appro... MEDIZINISCHE HOCHSCHULE HANNOVER tramitó un HORIZON EUROPE: HORIZON-HLTH-2021-DISEASE-04 Hepatitis D is by far the most severe form of chronic viral hepatitis frequently leading to liver failure, hepatocellular carcinoma and deat...
2022-05-25 - 2026-09-30 | Financiado
HEAL: HLA-homozygous iPSC-cardiomyocytE Aggregate manufacturing technoLogies for allogenic cell therapy to... MEDIZINISCHE HOCHSCHULE HANNOVER tramitó un HORIZON EUROPE: HORIZON-HLTH-2021-TOOL-06 HEAL will focus on general bottlenecks to induced pluripotent stem cell therapies with a particular focus on heart failure, which remains a...
2022-05-23 - 2026-02-28 | Financiado
* Datos extraídos de la documentos o webs disponibles en diferentes organismos públicos.